TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05970718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7544
Description: Solution for single ascending Intravenous (IV) or Subcutaneous (SC) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7544
Description: Solution for single ascending Intravenous (IV) or Subcutaneous (SC) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7544
Description: Solution for single ascending Intravenous (IV) or Subcutaneous (SC) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7544
Description: Solution for single ascending Intravenous (IV) or Subcutaneous (SC) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7544
Description: Solution for single ascending Intravenous (IV) or Subcutaneous (SC) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7544
Description: Solution for single ascending Intravenous (IV) or Subcutaneous (SC) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7544
Description: Solution for single ascending Intravenous (IV) or Subcutaneous (SC) administration
Study: NCT05526157

Intervention type: DRUG
Intervention: Non-steroidal mineral corticoid receptor antagonists (nsMRA)
Description: Retrospective analysis using secondary data collection from various sources
Study: NCT05970718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7544
Description: Solution for single ascending Intravenous (IV) or Subcutaneous (SC) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7544
Description: Solution for single ascending Intravenous (IV) or Subcutaneous (SC) administration
Study: NCT04965064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine and Neratinib.
Description: Neratinib 240 mg PO QD Daily On-going Capecitabine 750 mg/m2 PO bid Days 1-14, 7 days off On-going
Study: NCT05970718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7544
Description: Solution for single ascending Intravenous (IV) or Subcutaneous (SC) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7544
Description: Solution for single ascending Intravenous (IV) or Subcutaneous (SC) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Solution for single ascending IV or SC administration per the protocol
Study: NCT06713044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care (in control arm)
Description: To serve as a control group no intervention
Study: NCT06713512

Intervention type: OTHER
Intervention: No intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No intervention
Description: No Intervention
Study: NCT06714175

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower Limb Strength Training Program with Visual Feedback
Description: This lower limb explosive strength training system integrates visual feedback games and is equipped with angle and force sensors to simultaneously output the power of the left and right legs, as well as maximum explosive force and pushing force. Users can immediately understand the balance of leg strength and make adjustments, making it particularly suitable for the elderly to improve lower limb strength or for rehabilitation training. The gamification of the system enhances the fun of training, while data quantification allows progress tracking, making the training more precise and effective. Additionally, after the game ends, data can be exported to Excel for further analysis to identify issues in the pushing process and optimize the training plan.
Study: NCT06714331

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplements
Description: Supplements provided to subjects 2 hours prior to testing and drank at 2 hours, 90 minutes and 45 minutes before testing.

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Supplements
Description: Supplements provided to subjects 2 hours prior to testing and drank at 2 hours, 90 minutes and 45 minutes before testing.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplements
Description: Supplements provided to subjects 2 hours prior to testing and drank at 2 hours, 90 minutes and 45 minutes before testing.
Study: NCT06714383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: Trilaciclib: 240mg/m2, IV, within 4 hours before each chemotherapy agent infused.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Pirarubicin
Description: Pirarubicin: 60 mg/m2，IV，d1-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirarubicin
Description: Pirarubicin: 60 mg/m2，IV，d1-2

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Lobaplatin
Description: LobaplLatin: 40 mg/m2,，IV，d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobaplatin
Description: LobaplLatin: 40 mg/m2,，IV，d1
Study: NCT06710977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safety of intracameral levofloxacin in cataract surgery
Description: Intracameral levofloxacin (0.1ml/0.5mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Safety of intracameral levofloxacin in cataract surgery
Description: Intracameral levofloxacin (0.1ml/0.5mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Use of intracameral cefazolin in cataract surgery
Description: Intracameral cefazolin (0.1ml/1mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Use of intracameral cefazolin in cataract surgery
Description: Intracameral cefazolin (0.1ml/1mg)
Study: NCT06711146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metabolically Armed CD19 CAR-T cells
Description: Each subject receive metabolically armed CD19 CAR- T cells by intravenous infusion
Study: NCT06712394

Intervention type: PROCEDURE
Intervention: IPACK
Description: The IPACK block involves infiltration of the space between the popliteal artery and the posterior knee joint capsule with 20 ml of 0.25% local anesthetic (bupivacain) under ultrasound guidance.
Study: NCT06711367

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: tell show do behavior management technique
Description: tell show do behavior management technique about the the diagnosis and procedures of dental restoration

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a costume-designed storybook
Description: a costume-designed storybook explaining the diagnosis and procedures of dental restoration
Study: NCT06711016

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fluid resuscitation, vasoactive drug dose,hemoglobin transfusion,sedative analgesic muscle relaxant drugs, antiepileptic drugs, etc
Description: ECMO flow, IABP , ventilator support parameters, temperature management level and time

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluid resuscitation, vasoactive drug dose,hemoglobin transfusion,sedative analgesic muscle relaxant drugs, antiepileptic drugs, etc
Description: ECMO flow, IABP , ventilator support parameters, temperature management level and time
Study: NCT06712472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg BID)
Description: Olaparib 300mg Bid during one year.
Study: NCT06714604

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRINOX or gemcitabine-nab-paclitaxel
Description: 4 months if treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX or gemcitabine-nab-paclitaxel
Description: 6 months of treatment
Study: NCT06713863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BEtter At LEarning (BEATLE)- Digital Care Pathway
Description: BEATLE is a digital care pathway consisting of ten episodes resembling an online course. The episodes are designed to be multimodal and immersive, incorporating text, recorded voice, pictures, cartoons, videos and peer support through given examples and case stories. Participants are encouraged to access BEATLE through a web browser on a computer, although it is also accessible through a mobile application. Participants have control over the pace of completing the BEATLE, but there must be a minimum five-day break between episodes. In other words, it is possible to complete the BEATLE in seven weeks.~All participants are referred to the BEATLE by a neuropsychologist and are strongly authenticated in the healthvillage.fi online platform. Each participant is assigned a designated neuropsychologist who tracks their progress in the BEATLE and to whom messages and questions can be sent by the participant.
Study: NCT06711770

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample
Description: Four tubes of 7 mL collected at baseline, 3 weeks, 6 weeks, 12 weeks, 6 months, 12 months and 24 months (end of chemo-immunotherapy) or in case of relapse

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample
Description: Four tubes of 7 mL collected at baseline, 3 weeks, 6 weeks, 12 weeks, 6 months, 12 months and 24 months (end of chemo-immunotherapy) or in case of relapse
Study: NCT06711328

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New oropharyngeal airway
Description: This product is produced and sold by Shanghai Elifu Medical Technology Co., LTD., and has been officially put into clinical use in March 2023.The product is named oropharyngeal airway for disposable endoscope, which is composed of nasal plug, bite, oropharyngeal channel, oxygen supply tube, lanyard and optional accessories carbon dioxide gas catheter and carbon dioxide collection tube.The model used in this study is JK (Oropharyngeal airway for endoscope with end-expiratory carbon dioxide Collection) with L/M/S three specifications, which is used to prevent airway obstruction caused by backward tongue fall during endoscopic surgery/examination, establish oropharyngeal airway for patients, and provide nasal oxygen at the same time
Study: NCT06712797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Description: Participants will receive a Fitbit (Inspire 3, Google LLC, Mountain View, CA, USA) to encourage and self-monitor Physical Activity (PA) using active minutes, which approximate moderate-to-vigorous PA.~Fitbits will be synced to a HIPAA-compliant platform created by Moffitt's Biostatistics and Bioinformatics Shared Resource (BBSR).~Study personnel will view active minutes to provide individualized feedback and encourage progression. Weekly feedback will encourage participants to increase active minutes by 10% until achieving ≥ 150 minutes to meet cancer prevention recommendations.~Participants who reach ≥ 150 active minutes will be encouraged to maintain or exceed recommendations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition (N)
Description: Participants will undergo counseling at baseline (T0) to address nutritional symptoms and provide targets for daily calories and protein following a Mediterranean diet. This diet includes a high intake of vegetables, legumes, fruits, and unsaturated fatty acids, low intake of saturated fatty acids, and a moderately high intake of fish.~Total caloric intake will be calculated. A standard breakdown of 40% carbohydrates, 30% fats and 30% protein will be used. Individuals will review this calculation during their office encounters and follow these values using the FitBit, application, which will adjust to their daily energy expenditure.~Additional counseling (in-person or via Zoom) will occur at baseline (T0) + 12 weeks to gauge progress toward calorie and protein targets, monitor weight change, and guide dietary changes.~Participants will log daily food intake and self-monitor progress toward calorie and protein goals.
Study: NCT06711029

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional needle irrigation
Description: Conventional needle irrigation method was applied. As a final irrigation, 6 ml NaOCl was applied with 60 seconds of needle irrigation followed by 60 seconds of rest.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive Ultrasonic Irrigation with 3*20 sn
Description: In the final irrigation, 6 ml (3×2 ml) NaOCl was activated by PUI for 20 seconds in 3 cycles (60 seconds total). Before each cycle, 2 ml of NaOCl solution was refreshment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive Ultrasonic Irrigation with 6*10 sn
Description: For the final irrigation, 6 ml (6×1 ml) NaOCl was activated with PUI for 10 seconds in 6 cycles (60 seconds total). Before each cycle, 1 ml of NaOCl solution was refreshment.
Study: NCT06713434

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ELK-003 (Standarized Amniotic Fluid Secretome Eye Drops)
Description: ELK-003 eye drops are a standardized amniotic fluid secretome formulation. It contains essential extracellular matrix proteins, such as collagen type VII and laminin-332, which are critical for maintaining corneal integrity in EB patients. In addition, ELK-003 also includes growth factors that stimulate corneal healing and tissue regeneration. This combination of matrix proteins and growth factors aims to enhance corneal surface stability.
Study: NCT06393634

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone injection
Description: A single injection of testosterone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone injection
Description: A single injection of testosterone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone gel
Description: A daily dose of testosterone gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Oral
Description: A twice-daily pill of testosterone pill to swallow
Study: NCT05860881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus Topical Cream
Description: The intervention topical cream consists of sirolimus 1% in a vehicle. Patients randomised to the intervention will be required to apply the sirolimus topical cream to their face for 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cream containing only the base, or vehicle.
Study: NCT06544642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP5502
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP5502
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP5502
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP5502
Description: Oral
Study: NCT04966962

Intervention type: DIAGNOSTIC_TEST
Intervention: serum and urine metabolomics
Description: serum and urine samples will be collected for metabolomics analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: serum and urine metabolomics
Description: serum and urine samples will be collected for metabolomics analysis
Study: NCT05855824

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Applesauce Pouch
Description: One 90 g pouch of applesauce provides 0 mg carotenoids/d and 40 kcal, 10 mg vitamin C, and 1 g dietary fiber.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Applesauce Pouch
Description: One 90 g pouch of applesauce provides 0 mg carotenoids/d and 40 kcal, 10 mg vitamin C, and 1 g dietary fiber.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit-vegetable puree blend
Description: One 120 g pouch of fruit-vegetable puree blend provides 5 mg mixed carotenoids, 70 kcal, 4 mg vitamin C, and 2 g dietary fiber.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit-vegetable puree blend
Description: One 120 g pouch of fruit-vegetable puree blend provides 5 mg mixed carotenoids, 70 kcal, 4 mg vitamin C, and 2 g dietary fiber.
Study: NCT04841967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TELL Tool Intervention
Description: A 60-minute session with decision support information delivered digitally to parents at their homes or other private, quiet location.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eBook Attention Control
Description: A 60-minute session with good parenting principles delivered digitally to parents at their homes or other private, quiet location.
Study: NCT05885386

Intervention type: DRUG
Group type: OTHER
Intervention: Temozolomide
Description: TMZ was administered orally at an initial daily dose of 150 mg/m2 per day for 5 days, every 28 days preoperatively. In patients with a good tolerance during the first cycle, the dose was increased to 200 mg/m2 per day for 5 days, every 28 days.
Study: NCT06383091

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Neck Manual Therapy
Description: Manual massage applied to the anterior neck, including hyolaryngeal elevators, depressors, sternocleidomastoid.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Neuroscience Education
Description: Description of how the pain system works from a neurobiological level, discussing the biopsychosocial model that influences pain.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neck Stretches
Description: Bilateral cervical side bending, cervical extension and bilateral rotational neck stretches held for 20 seconds x3.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Scar massage
Description: Digital manipulation of the scar itself in circles.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Scar massage
Description: Digital manipulation of the scar itself in circles.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voice Exercises
Description: Stemple Voice Exercises

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Voice Exercises
Description: Stemple Voice Exercises

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Anterior Neck Manual Therapy
Description: Will apply extremely light manual contact to the anterior neck, including hyolaryngeal elevators, depressors, sternocleidomastoid.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pain Neuroscience Education
Description: Will discuss how pain will as a result of the surgical intervention.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Neck Stretches
Description: Will ask patient to look down as a neck stretch held for 20 seconds x3.
Study: NCT05761587

Intervention type: OTHER
Intervention: Questionnaires
Description: questionnaire including socio-demographic data, medical and family history, lifestyle, treatments, 5 questions from the Questionnaire Concis sur les Douleurs (QCD), the French version of the POMI scale, the diagnostic criteria of the DSM-V and two questions concerning anxiety associated with pain and therapeutic education.
Study: NCT05008120

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05970718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Solution for single ascending IV or SC administration per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Solution for single ascending IV or SC administration per the protocol
Study: NCT05020769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B001
Description: SI-B001 is administered by intravenous drip once weekly (QW). 120 min ± 10 min after the first intravenous drip, if the infusion reaction is tolerable during the first dose, the subsequent infusion can be completed within 60-120 min (unless agreed or required by the investigator, the infusion time can be extended).
Study: NCT05970718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Solution for single ascending IV or SC administration per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Solution for single ascending IV or SC administration per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Solution for single ascending IV or SC administration per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Solution for single ascending IV or SC administration per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Solution for single ascending IV or SC administration per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Solution for single ascending IV or SC administration per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Solution for single ascending IV or SC administration per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Solution for single ascending IV or SC administration per the protocol
Study: NCT04776031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: R:GEN Laser System
Description: Laser Treatment
Study: NCT05712876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-0045
Description: Interleukin-22 agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-0045
Description: Interleukin-22 agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT06515977

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TXI (Group A)
Description: Patients in Group A will undergo colonoscopy with TXI.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TXI followed by WLI (Group B)
Description: Patients in group B will first undergo colonoscopy with TXI and every polyp found should be removed. Then switch to WLI for a second withdrawal to detect lesions that were not observed the first time.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: WLI (Group C)
Description: Patients in Group C will undergo colonoscopy with WLI.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: WLI followed by TXI (Group D)
Description: Patients in group D will first undergo colonoscopy with WLI and every polyp found should be removed. Then switch to TXI for a second withdrawal to detect lesions that were not observed the first time.
Study: NCT06544642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral
Study: NCT06392256

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non surgical therapy
Description: Non-surgical submarginal instrumentation using titanium curettes with saline irrigation will be done once in the treatment session.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non surgical therapy
Description: Non-surgical submarginal instrumentation using titanium curettes with saline irrigation will be done once in the treatment session.